[3H]MK-801 binding to NMDA glutamatergic receptors in Parkinson's disease and progressive supranuclear palsy
Identifieur interne : 000548 ( Istex/Corpus ); précédent : 000547; suivant : 000549[3H]MK-801 binding to NMDA glutamatergic receptors in Parkinson's disease and progressive supranuclear palsy
Auteurs : Sophie Holemans ; France Javoy ; Yves Agid ; E. Christian Laterre ; Jean-Marie MaloteauxSource :
- Brain Research [ 0006-8993 ] ; 1991.
English descriptors
- KwdEn :
Abstract
The interactions existing between glutamatergic and dopaminergic systems, notably in the basal ganglia, suggest that glutamatergic antagonists may have therapeutic interest in extrapyramidal disorders characterized by impaired dopaminergic transmission. The binding of [3H]dizocilpine maleate (MK-801) to glutamate receptors of the N-methyl-d-aspartate (NMDA)-subtypes was characterized in temporal and frontal cortex, in hippocampus and in subcortical areas (caudate nucleus and putamen) from controls and patients with Parkinson's disease or progressive supranuclear palsy. The binding affinity (KD) and the maximal specific binding capacity (Bmax) of [3H]MK-801 were unchanged in all the cerebral regions studied in both disease. This indicates the existence of preserved NMDA glutamate receptors, which is required for potential therapeutic efficacy of specific antagonists.
Url:
DOI: 10.1016/0006-8993(91)91747-O
Links to Exploration step
ISTEX:E84A3C69F12B98A24C9A2D9AFD53ACE76817ACA4Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">[3H]MK-801 binding to NMDA glutamatergic receptors in Parkinson's disease and progressive supranuclear palsy</title><author><name sortKey="Holemans, Sophie" sort="Holemans, Sophie" uniqKey="Holemans S" first="Sophie" last="Holemans">Sophie Holemans</name><affiliation><mods:affiliation>Laboratoire de Neurochimie, Université Catholique de Louvain, Brussels Belgium</mods:affiliation></affiliation></author><author><name sortKey="Javoy, France" sort="Javoy, France" uniqKey="Javoy F" first="France" last="Javoy">France Javoy</name><affiliation><mods:affiliation>Laboratoire de Médecine Expérimentale, INSERM U 289, CHU Pitié-Salpêtrière, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Agid, Yves" sort="Agid, Yves" uniqKey="Agid Y" first="Yves" last="Agid">Yves Agid</name><affiliation><mods:affiliation>Laboratoire de Médecine Expérimentale, INSERM U 289, CHU Pitié-Salpêtrière, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Laterre, E Christian" sort="Laterre, E Christian" uniqKey="Laterre E" first="E. Christian" last="Laterre">E. Christian Laterre</name><affiliation><mods:affiliation>Laboratoire de Neurochimie, Université Catholique de Louvain, Brussels Belgium</mods:affiliation></affiliation></author><author><name sortKey="Maloteaux, Jean Marie" sort="Maloteaux, Jean Marie" uniqKey="Maloteaux J" first="Jean-Marie" last="Maloteaux">Jean-Marie Maloteaux</name><affiliation><mods:affiliation>Correspondence: J.-M. Maloteaux, Laboratoire de Neurochimie et Service de Neurologie (1352), Université Catholique de Louvain, Avenue Hippocrate, 10, B-1200 Brussels, Belgium.</mods:affiliation></affiliation><affiliation><mods:affiliation>Laboratoire de Neurochimie, Université Catholique de Louvain, Brussels Belgium</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:E84A3C69F12B98A24C9A2D9AFD53ACE76817ACA4</idno><date when="1991" year="1991">1991</date><idno type="doi">10.1016/0006-8993(91)91747-O</idno><idno type="url">https://api.istex.fr/document/E84A3C69F12B98A24C9A2D9AFD53ACE76817ACA4/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000548</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000548</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">[3H]MK-801 binding to NMDA glutamatergic receptors in Parkinson's disease and progressive supranuclear palsy</title><author><name sortKey="Holemans, Sophie" sort="Holemans, Sophie" uniqKey="Holemans S" first="Sophie" last="Holemans">Sophie Holemans</name><affiliation><mods:affiliation>Laboratoire de Neurochimie, Université Catholique de Louvain, Brussels Belgium</mods:affiliation></affiliation></author><author><name sortKey="Javoy, France" sort="Javoy, France" uniqKey="Javoy F" first="France" last="Javoy">France Javoy</name><affiliation><mods:affiliation>Laboratoire de Médecine Expérimentale, INSERM U 289, CHU Pitié-Salpêtrière, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Agid, Yves" sort="Agid, Yves" uniqKey="Agid Y" first="Yves" last="Agid">Yves Agid</name><affiliation><mods:affiliation>Laboratoire de Médecine Expérimentale, INSERM U 289, CHU Pitié-Salpêtrière, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Laterre, E Christian" sort="Laterre, E Christian" uniqKey="Laterre E" first="E. Christian" last="Laterre">E. Christian Laterre</name><affiliation><mods:affiliation>Laboratoire de Neurochimie, Université Catholique de Louvain, Brussels Belgium</mods:affiliation></affiliation></author><author><name sortKey="Maloteaux, Jean Marie" sort="Maloteaux, Jean Marie" uniqKey="Maloteaux J" first="Jean-Marie" last="Maloteaux">Jean-Marie Maloteaux</name><affiliation><mods:affiliation>Correspondence: J.-M. Maloteaux, Laboratoire de Neurochimie et Service de Neurologie (1352), Université Catholique de Louvain, Avenue Hippocrate, 10, B-1200 Brussels, Belgium.</mods:affiliation></affiliation><affiliation><mods:affiliation>Laboratoire de Neurochimie, Université Catholique de Louvain, Brussels Belgium</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Brain Research</title><title level="j" type="abbrev">BRES</title><idno type="ISSN">0006-8993</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1991">1991</date><biblScope unit="volume">565</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="154">154</biblScope><biblScope unit="page" to="157">157</biblScope></imprint><idno type="ISSN">0006-8993</idno></series><idno type="istex">E84A3C69F12B98A24C9A2D9AFD53ACE76817ACA4</idno><idno type="DOI">10.1016/0006-8993(91)91747-O</idno><idno type="PII">0006-8993(91)91747-O</idno><idno type="ArticleID">9191747O</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0006-8993</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Glutamate antagonist</term><term>Human brain</term><term>N-methyl-d-aspartate receptors</term><term>Parkinson's disease</term><term>Progressive supranuclear palsy</term><term>[3H]Dizocilpine maleate</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The interactions existing between glutamatergic and dopaminergic systems, notably in the basal ganglia, suggest that glutamatergic antagonists may have therapeutic interest in extrapyramidal disorders characterized by impaired dopaminergic transmission. The binding of [3H]dizocilpine maleate (MK-801) to glutamate receptors of the N-methyl-d-aspartate (NMDA)-subtypes was characterized in temporal and frontal cortex, in hippocampus and in subcortical areas (caudate nucleus and putamen) from controls and patients with Parkinson's disease or progressive supranuclear palsy. The binding affinity (KD) and the maximal specific binding capacity (Bmax) of [3H]MK-801 were unchanged in all the cerebral regions studied in both disease. This indicates the existence of preserved NMDA glutamate receptors, which is required for potential therapeutic efficacy of specific antagonists.</div></front></TEI><istex><corpusName>elsevier</corpusName><author><json:item><name>Sophie Holemans</name><affiliations><json:string>Laboratoire de Neurochimie, Université Catholique de Louvain, Brussels Belgium</json:string></affiliations></json:item><json:item><name>France Javoy</name><affiliations><json:string>Laboratoire de Médecine Expérimentale, INSERM U 289, CHU Pitié-Salpêtrière, Paris, France</json:string></affiliations></json:item><json:item><name>Yves Agid</name><affiliations><json:string>Laboratoire de Médecine Expérimentale, INSERM U 289, CHU Pitié-Salpêtrière, Paris, France</json:string></affiliations></json:item><json:item><name>E.Christian Laterre</name><affiliations><json:string>Laboratoire de Neurochimie, Université Catholique de Louvain, Brussels Belgium</json:string></affiliations></json:item><json:item><name>Jean-Marie Maloteaux</name><affiliations><json:string>Correspondence: J.-M. Maloteaux, Laboratoire de Neurochimie et Service de Neurologie (1352), Université Catholique de Louvain, Avenue Hippocrate, 10, B-1200 Brussels, Belgium.</json:string><json:string>Laboratoire de Neurochimie, Université Catholique de Louvain, Brussels Belgium</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>N-methyl-d-aspartate receptors</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Human brain</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>[3H]Dizocilpine maleate</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Progressive supranuclear palsy</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Glutamate antagonist</value></json:item></subject><articleId><json:string>9191747O</json:string></articleId><language><json:string>eng</json:string></language><originalGenre><json:string>Full-length article</json:string></originalGenre><abstract>The interactions existing between glutamatergic and dopaminergic systems, notably in the basal ganglia, suggest that glutamatergic antagonists may have therapeutic interest in extrapyramidal disorders characterized by impaired dopaminergic transmission. The binding of [3H]dizocilpine maleate (MK-801) to glutamate receptors of the N-methyl-d-aspartate (NMDA)-subtypes was characterized in temporal and frontal cortex, in hippocampus and in subcortical areas (caudate nucleus and putamen) from controls and patients with Parkinson's disease or progressive supranuclear palsy. The binding affinity (KD) and the maximal specific binding capacity (Bmax) of [3H]MK-801 were unchanged in all the cerebral regions studied in both disease. This indicates the existence of preserved NMDA glutamate receptors, which is required for potential therapeutic efficacy of specific antagonists.</abstract><qualityIndicators><score>3.81</score><pdfVersion>1.2</pdfVersion><pdfPageSize>576 x 792 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>6</keywordCount><abstractCharCount>878</abstractCharCount><pdfWordCount>2454</pdfWordCount><pdfCharCount>16501</pdfCharCount><pdfPageCount>4</pdfPageCount><abstractWordCount>113</abstractWordCount></qualityIndicators><title>[3H]MK-801 binding to NMDA glutamatergic receptors in Parkinson's disease and progressive supranuclear palsy</title><pii><json:string>0006-8993(91)91747-O</json:string></pii><refBibs><json:item><author><json:item><name>Y. Agid</name></json:item><json:item><name>F. Javoy-Agid</name></json:item><json:item><name>M. Ruberg</name></json:item></author><host><author></author><title>Movement Disorders 2, BMIR Neurology</title></host><serie><author></author><title>Movement Disorders 2, BMIR Neurology</title></serie><title>Biochemistry of neurotransmitters in Parkinson's disease</title></json:item><json:item><author><json:item><name>R.L. Albin</name></json:item><json:item><name>A.B. Young</name></json:item><json:item><name>J.B. Penney</name></json:item><json:item><name>B. Handelin</name></json:item><json:item><name>R. Balfour</name></json:item><json:item><name>K.D. Anderson</name></json:item><json:item><name>D.S. Markel</name></json:item><json:item><name>W.W. Tourtellote</name></json:item><json:item><name>A. Reiner</name></json:item></author><host><volume>322</volume><pages><last>1298</last><first>1293</first></pages><author></author><title>N. Engl. J. Med.</title></host><title>Abnormalities of striatal projection neurons and N-methyl-d-aspartate receptors in presymptomatic Huntington's disease</title></json:item><json:item><author><json:item><name>M.F. Beal</name></json:item><json:item><name>N.W. Kowall</name></json:item><json:item><name>D.W. Ellison</name></json:item><json:item><name>M.F. Mazurek</name></json:item><json:item><name>K.J. Swartz</name></json:item><json:item><name>J.B. Martin</name></json:item></author><host><volume>321</volume><pages><last>171</last><first>168</first></pages><author></author><title>Nature</title></host><title>Replication of neurochemical characteristics of Huntington's disease by quinolinic acid</title></json:item><json:item><author><json:item><name>H. Bergman</name></json:item><json:item><name>T. Wichmann</name></json:item><json:item><name>M.R. DeLong</name></json:item></author><host><volume>249</volume><pages><last>1438</last><first>1436</first></pages><author></author><title>Science</title></host><title>Reversal of experimental Parkinsonism by lesions of the subthalamic nucleus</title></json:item><json:item><author><json:item><name>B. Bokobza</name></json:item><json:item><name>M. Ruberg</name></json:item><json:item><name>B. Scatton</name></json:item><json:item><name>F. Javoy-Agid</name></json:item><json:item><name>Y. Agid</name></json:item></author><host><volume>99</volume><pages><last>175</last><first>167</first></pages><author></author><title>Eur. J. Pharmacol.</title></host><title>3H-Spiperone binding, dopamine and HVA concentrations in Parkinson's disease and supranuclear palsy</title></json:item><json:item><author><json:item><name>M. Carlsson</name></json:item><json:item><name>A. Carlsson</name></json:item></author><host><volume>75</volume><pages><last>226</last><first>221</first></pages><author></author><title>J. Neural Transm.</title></host><title>The NMDA antogonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice</title></json:item><json:item><author><json:item><name>M. Carlsson</name></json:item><json:item><name>A. Carlsson</name></json:item></author><host><volume>77</volume><pages><last>71</last><first>65</first></pages><author></author><title>J. Neural Transm.</title></host><title>Dramatic synergism between MK-801 and clonidine with respect to locomotor stimulatory effect in monoamine-depleted mice</title></json:item><json:item><author><json:item><name>M. Carlsson</name></json:item><json:item><name>A. Carlsson</name></json:item></author><host><volume>13</volume><pages><last>276</last><first>272</first></pages><author></author><title>Trends Neurosci.</title></host><title>Interactions between glutamatergic and monoaminergic systems within the basal ganglia - implications for schizophrenia and Parkinson's disease</title></json:item><json:item><author><json:item><name>G.L. Collingridge</name></json:item><json:item><name>R.A.J. Lester</name></json:item></author><host><volume>40</volume><pages><last>210</last><first>143</first></pages><author></author><title>Pharmacol. Rev.</title></host><title>Excitatory amino acid receptors in the vertebrate central nervous system</title></json:item><json:item><author><json:item><name>L.S. Dure</name></json:item><json:item><name>J.B. Penney</name></json:item><json:item><name>A.B. Young</name></json:item></author><host><volume>5</volume><pages><first>39</first></pages><author></author><title>Mov. Disord.</title></host><title>[3H]Glycine and [3H]MK-801 binding in the basal ganglia in Huntington's disease</title></json:item><json:item><author><json:item><name>R.J. Ferrante</name></json:item><json:item><name>N.W. Kowall</name></json:item><json:item><name>M.F. Beal</name></json:item><json:item><name>E.P. Richardson</name></json:item><json:item><name>E.D. Bird</name></json:item><json:item><name>J.B. Martin</name></json:item></author><host><volume>230</volume><pages><last>563</last><first>561</first></pages><author></author><title>Science</title></host><title>Selective sparing of a class of striatal neurons in Huntington's disease</title></json:item><json:item><author><json:item><name>J.-A. Girault</name></json:item><json:item><name>R. Raisman-Vozari</name></json:item><json:item><name>Y. Agid</name></json:item><json:item><name>P. Greengard</name></json:item></author><host><author></author><title>Proc. Natl. Acad. Sci. U.S.A.</title></host><serie><author></author><title>Proc. Natl. Acad. Sci. U.S.A.</title></serie><title>Striatal phosphoproteins in Parkinson disease and progressive supranuclear palsy</title></json:item><json:item><author><json:item><name>J.-A. Girault</name></json:item><json:item><name>S. Halpain</name></json:item><json:item><name>P. Greengard</name></json:item></author><host><volume>13</volume><pages><last>326</last><first>325</first></pages><author></author><title>Trends Neurosci.</title></host><title>Excitatory amino acid antagonists and Parkinson's disease</title></json:item><json:item><author><json:item><name>J.T. Greenamyre</name></json:item><json:item><name>A.B. Young</name></json:item></author><host><volume>101</volume><pages><last>137</last><first>133</first></pages><author></author><title>Neurosci. Lett.</title></host><title>Synaptic localization of striatal NMDA, quisqualate and kainate receptors</title></json:item><json:item><author><json:item><name>S. Halpain</name></json:item><json:item><name>J.-A. Girault</name></json:item><json:item><name>P. Greengard</name></json:item></author><host><volume>343</volume><pages><last>372</last><first>369</first></pages><author></author><title>Nature</title></host><title>Activation of NMDA receptors induces dephophorylation of DARPP-32 in rat striatal mice</title></json:item><json:item><author><json:item><name>A. Hudson</name></json:item><json:item><name>G.N. Woodruff</name></json:item></author><host><volume>97</volume><pages><first>576</first></pages><author></author><title>Br. J. Pharmacol.</title></host><title>Localisation of [3H]-MK-801 binding sites in rat brain following lesions of striatum or substantia nigra</title></json:item><json:item><author><json:item><name>O.H. Lowry</name></json:item><json:item><name>N.J. Rosebrough</name></json:item><json:item><name>A.L. Farr</name></json:item><json:item><name>R.J. Randall</name></json:item></author><host><volume>193</volume><pages><last>275</last><first>265</first></pages><author></author><title>J. Biol. Chem.</title></host><title>Protein measurement with the Folin phenol reagent</title></json:item><json:item><author><json:item><name>J.W. Olney</name></json:item></author><host><volume>26</volume><pages><last>525</last><first>505</first></pages><author></author><title>Biol. Psychiatr.</title></host><title>Excitatory amino acids and neuropsychiatric disorders</title></json:item><json:item><author><json:item><name>R. Raisman-Vosari</name></json:item><json:item><name>J.-A. Girault</name></json:item><json:item><name>S. Moussaoui</name></json:item><json:item><name>C. Feuerstein</name></json:item><json:item><name>P. Jenner</name></json:item><json:item><name>C.D. Marsden</name></json:item><json:item><name>Y. Agid</name></json:item></author><host><volume>507</volume><pages><last>50</last><first>45</first></pages><author></author><title>Brain Research</title></host><title>Lack of change in striatal DARPP-32 levels following nigrostriatal dopaminergic lesions in animals and in parkinsonian syndromes in man</title></json:item><json:item><author><json:item><name>P.J. Roberts</name></json:item><json:item><name>N.A. Sharif</name></json:item></author><host><volume>157</volume><pages><last>395</last><first>391</first></pages><author></author><title>Brain Research</title></host><title>Effects of l-glutamate and related amino acids upon the release of [3H]dopamine from rat striatal slices</title></json:item><json:item><author><json:item><name>P.J. Roberts</name></json:item><json:item><name>S.D. Anderson</name></json:item></author><host><volume>32</volume><pages><last>1545</last><first>1539</first></pages><author></author><title>J. Neurochem.</title></host><title>Stimulatory effects of l-glutamate and related amino acids on [3H]dopamine release from rat striatum: an in vitro model for glutamate actions</title></json:item><json:item><author><json:item><name>M. Ruberg</name></json:item><json:item><name>F. Javoy-Agid</name></json:item><json:item><name>E. Hirsch</name></json:item><json:item><name>B. Seatton</name></json:item><json:item><name>B. Lhereux</name></json:item><json:item><name>J.-J. Hauw</name></json:item><json:item><name>C. Duyckaerts</name></json:item><json:item><name>F. Gray</name></json:item><json:item><name>A. Morel-Maroger</name></json:item><json:item><name>A. Rascol</name></json:item><json:item><name>M. Serdaru</name></json:item><json:item><name>Y. Agid</name></json:item></author><host><volume>18</volume><pages><last>529</last><first>523</first></pages><author></author><title>Ann. Neurol.</title></host><title>Dopaminergic and cholinergic lesions in progressive supranuclear palsy</title></json:item><json:item><author><json:item><name>R. Schwarez</name></json:item><json:item><name>W.O. Whetsell</name></json:item><json:item><name>R.M. Mangano</name></json:item></author><host><volume>219</volume><pages><last>318</last><first>316</first></pages><author></author><title>Science</title></host><title>Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain</title></json:item><json:item><author><json:item><name>L. Turski</name></json:item><json:item><name>K. Bressler</name></json:item><json:item><name>K.-J. Rettig</name></json:item><json:item><name>P.-A. Löschmann</name></json:item><json:item><name>H. Wachtel</name></json:item></author><host><volume>349</volume><pages><last>418</last><first>414</first></pages><author></author><title>Nature</title></host><title>Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-d-asparatate antagonists</title></json:item><json:item><author><json:item><name>A.B. Young</name></json:item><json:item><name>J.T. Greenamyre</name></json:item><json:item><name>Z. Hollingsworth</name></json:item><json:item><name>R. Albin</name></json:item><json:item><name>C. D'Amato</name></json:item><json:item><name>I. Shoulson</name></json:item><json:item><name>J.B. Penney</name></json:item></author><host><volume>241</volume><pages><last>988</last><first>981</first></pages><author></author><title>Science</title></host><title>NMDA receptor losses in putamen from patients with Huntington's disease</title></json:item></refBibs><genre><json:string>research-article</json:string></genre><serie><volume>Vol. 7</volume><pages><last>230</last><first>166</first></pages><language><json:string>unknown</json:string></language><title>Movement Disorders 2, BMIR Neurology</title></serie><host><volume>565</volume><pii><json:string>S0006-8993(00)X1481-3</json:string></pii><pages><last>157</last><first>154</first></pages><issn><json:string>0006-8993</json:string></issn><issue>1</issue><genre><json:string>journal</json:string></genre><language><json:string>unknown</json:string></language><title>Brain Research</title><publicationDate>1991</publicationDate></host><categories><wos><json:string>science</json:string><json:string>neurosciences</json:string></wos><scienceMetrix><json:string>health sciences</json:string><json:string>clinical medicine</json:string><json:string>neurology & neurosurgery</json:string></scienceMetrix></categories><publicationDate>1991</publicationDate><copyrightDate>1991</copyrightDate><doi><json:string>10.1016/0006-8993(91)91747-O</json:string></doi><id>E84A3C69F12B98A24C9A2D9AFD53ACE76817ACA4</id><score>0.105586186</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/document/E84A3C69F12B98A24C9A2D9AFD53ACE76817ACA4/fulltext/pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/document/E84A3C69F12B98A24C9A2D9AFD53ACE76817ACA4/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/E84A3C69F12B98A24C9A2D9AFD53ACE76817ACA4/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">[3H]MK-801 binding to NMDA glutamatergic receptors in Parkinson's disease and progressive supranuclear palsy</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>ELSEVIER</publisher><availability><p>ELSEVIER</p></availability><date>1991</date></publicationStmt><notesStmt><note type="content">Section title: Research report</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">[3H]MK-801 binding to NMDA glutamatergic receptors in Parkinson's disease and progressive supranuclear palsy</title><author xml:id="author-1"><persName><forename type="first">Sophie</forename><surname>Holemans</surname></persName><affiliation>Laboratoire de Neurochimie, Université Catholique de Louvain, Brussels Belgium</affiliation></author><author xml:id="author-2"><persName><forename type="first">France</forename><surname>Javoy</surname></persName><affiliation>Laboratoire de Médecine Expérimentale, INSERM U 289, CHU Pitié-Salpêtrière, Paris, France</affiliation></author><author xml:id="author-3"><persName><forename type="first">Yves</forename><surname>Agid</surname></persName><affiliation>Laboratoire de Médecine Expérimentale, INSERM U 289, CHU Pitié-Salpêtrière, Paris, France</affiliation></author><author xml:id="author-4"><persName><forename type="first">E.Christian</forename><surname>Laterre</surname></persName><affiliation>Laboratoire de Neurochimie, Université Catholique de Louvain, Brussels Belgium</affiliation></author><author xml:id="author-5"><persName><forename type="first">Jean-Marie</forename><surname>Maloteaux</surname></persName><affiliation>Correspondence: J.-M. Maloteaux, Laboratoire de Neurochimie et Service de Neurologie (1352), Université Catholique de Louvain, Avenue Hippocrate, 10, B-1200 Brussels, Belgium.</affiliation><affiliation>Laboratoire de Neurochimie, Université Catholique de Louvain, Brussels Belgium</affiliation></author></analytic><monogr><title level="j">Brain Research</title><title level="j" type="abbrev">BRES</title><idno type="pISSN">0006-8993</idno><idno type="PII">S0006-8993(00)X1481-3</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1991"></date><biblScope unit="volume">565</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="154">154</biblScope><biblScope unit="page" to="157">157</biblScope></imprint></monogr><idno type="istex">E84A3C69F12B98A24C9A2D9AFD53ACE76817ACA4</idno><idno type="DOI">10.1016/0006-8993(91)91747-O</idno><idno type="PII">0006-8993(91)91747-O</idno><idno type="ArticleID">9191747O</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1991</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>The interactions existing between glutamatergic and dopaminergic systems, notably in the basal ganglia, suggest that glutamatergic antagonists may have therapeutic interest in extrapyramidal disorders characterized by impaired dopaminergic transmission. The binding of [3H]dizocilpine maleate (MK-801) to glutamate receptors of the N-methyl-d-aspartate (NMDA)-subtypes was characterized in temporal and frontal cortex, in hippocampus and in subcortical areas (caudate nucleus and putamen) from controls and patients with Parkinson's disease or progressive supranuclear palsy. The binding affinity (KD) and the maximal specific binding capacity (Bmax) of [3H]MK-801 were unchanged in all the cerebral regions studied in both disease. This indicates the existence of preserved NMDA glutamate receptors, which is required for potential therapeutic efficacy of specific antagonists.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>N-methyl-d-aspartate receptors</term></item><item><term>Human brain</term></item><item><term>[3H]Dizocilpine maleate</term></item><item><term>Parkinson's disease</term></item><item><term>Progressive supranuclear palsy</term></item><item><term>Glutamate antagonist</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1991">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/document/E84A3C69F12B98A24C9A2D9AFD53ACE76817ACA4/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Elsevier, elements deleted: tail"><istex:xmlDeclaration>version="1.0" encoding="UTF-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//ES//DTD journal article DTD version 4.5.2//EN//XML" URI="art452.dtd" name="istex:docType"></istex:docType><istex:document><converted-article version="4.5.2" docsubtype="fla" xml:lang="en"><item-info><jid>BRES</jid><aid>9191747O</aid><ce:pii>0006-8993(91)91747-O</ce:pii><ce:doi>10.1016/0006-8993(91)91747-O</ce:doi><ce:copyright type="unknown" year="1991"></ce:copyright></item-info><head><ce:dochead><ce:textfn>Research report</ce:textfn></ce:dochead><ce:title>[<ce:sup loc="pre">3</ce:sup>H]MK-801 binding to NMDA glutamatergic receptors in Parkinson's disease and progressive supranuclear palsy</ce:title><ce:author-group><ce:author><ce:given-name>Sophie</ce:given-name><ce:surname>Holemans</ce:surname><ce:cross-ref refid="AFF1"><ce:sup loc="post">1</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>France</ce:given-name><ce:surname>Javoy</ce:surname><ce:cross-ref refid="AFF2"><ce:sup loc="post">2</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Yves</ce:given-name><ce:surname>Agid</ce:surname><ce:cross-ref refid="AFF2"><ce:sup loc="post">2</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>E.Christian</ce:given-name><ce:surname>Laterre</ce:surname><ce:cross-ref refid="AFF1"><ce:sup loc="post">1</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Jean-Marie</ce:given-name><ce:surname>Maloteaux</ce:surname><ce:cross-ref refid="COR1"><ce:sup loc="post">∗</ce:sup></ce:cross-ref><ce:cross-ref refid="AFF1"><ce:sup loc="post">1</ce:sup></ce:cross-ref></ce:author><ce:affiliation id="AFF1"><ce:label>1</ce:label><ce:textfn>Laboratoire de Neurochimie, Université Catholique de Louvain, Brussels Belgium</ce:textfn></ce:affiliation><ce:affiliation id="AFF2"><ce:label>2</ce:label><ce:textfn>Laboratoire de Médecine Expérimentale, INSERM U 289, CHU Pitié-Salpêtrière, Paris, France</ce:textfn></ce:affiliation><ce:correspondence id="COR1"><ce:label>∗</ce:label><ce:text><ce:italic>Correspondence:</ce:italic> J.-M. Maloteaux, Laboratoire de Neurochimie et Service de Neurologie (1352), Université Catholique de Louvain, Avenue Hippocrate, 10, B-1200 Brussels, Belgium.</ce:text></ce:correspondence></ce:author-group><ce:date-accepted day="9" month="7" year="1991"></ce:date-accepted><ce:abstract class="author"><ce:section-title>Abstract</ce:section-title><ce:abstract-sec><ce:simple-para view="all" id="simple-para.0010">The interactions existing between glutamatergic and dopaminergic systems, notably in the basal ganglia, suggest that glutamatergic antagonists may have therapeutic interest in extrapyramidal disorders characterized by impaired dopaminergic transmission. The binding of [<ce:sup loc="pre">3</ce:sup>H]dizocilpine maleate (MK-801) to glutamate receptors of the <math altimg="si1.gif">N-<rm>methyl-<scp>d</scp>-aspartate</rm></math> (NMDA)-subtypes was characterized in temporal and frontal cortex, in hippocampus and in subcortical areas (caudate nucleus and putamen) from controls and patients with Parkinson's disease or progressive supranuclear palsy. The binding affinity (<ce:italic>K</ce:italic><ce:inf loc="post">D</ce:inf>) and the maximal specific binding capacity (<ce:italic>B</ce:italic><ce:inf loc="post">max</ce:inf>) of [<ce:sup loc="pre">3</ce:sup>H]MK-801 were unchanged in all the cerebral regions studied in both disease. This indicates the existence of preserved NMDA glutamate receptors, which is required for potential therapeutic efficacy of specific antagonists.</ce:simple-para></ce:abstract-sec></ce:abstract><ce:keywords class="keyword"><ce:section-title>Keywords</ce:section-title><ce:keyword><ce:text><math altimg="si2.gif">N-<rm>methyl-<scp>d</scp>-aspartate</rm></math> receptors</ce:text></ce:keyword><ce:keyword><ce:text>Human brain</ce:text></ce:keyword><ce:keyword><ce:text>[<ce:sup loc="pre">3</ce:sup>H]Dizocilpine maleate</ce:text></ce:keyword><ce:keyword><ce:text>Parkinson's disease</ce:text></ce:keyword><ce:keyword><ce:text>Progressive supranuclear palsy</ce:text></ce:keyword><ce:keyword><ce:text>Glutamate antagonist</ce:text></ce:keyword></ce:keywords></head></converted-article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>[3H]MK-801 binding to NMDA glutamatergic receptors in Parkinson's disease and progressive supranuclear palsy</title></titleInfo><titleInfo type="alternative" lang="en" contentType="CDATA"><title>[</title></titleInfo><name type="personal"><namePart type="given">Sophie</namePart><namePart type="family">Holemans</namePart><affiliation>Laboratoire de Neurochimie, Université Catholique de Louvain, Brussels Belgium</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">France</namePart><namePart type="family">Javoy</namePart><affiliation>Laboratoire de Médecine Expérimentale, INSERM U 289, CHU Pitié-Salpêtrière, Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Yves</namePart><namePart type="family">Agid</namePart><affiliation>Laboratoire de Médecine Expérimentale, INSERM U 289, CHU Pitié-Salpêtrière, Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">E.Christian</namePart><namePart type="family">Laterre</namePart><affiliation>Laboratoire de Neurochimie, Université Catholique de Louvain, Brussels Belgium</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Jean-Marie</namePart><namePart type="family">Maloteaux</namePart><affiliation>Correspondence: J.-M. Maloteaux, Laboratoire de Neurochimie et Service de Neurologie (1352), Université Catholique de Louvain, Avenue Hippocrate, 10, B-1200 Brussels, Belgium.</affiliation><affiliation>Laboratoire de Neurochimie, Université Catholique de Louvain, Brussels Belgium</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="Full-length article"></genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">1991</dateIssued><copyrightDate encoding="w3cdtf">1991</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract lang="en">The interactions existing between glutamatergic and dopaminergic systems, notably in the basal ganglia, suggest that glutamatergic antagonists may have therapeutic interest in extrapyramidal disorders characterized by impaired dopaminergic transmission. The binding of [3H]dizocilpine maleate (MK-801) to glutamate receptors of the N-methyl-d-aspartate (NMDA)-subtypes was characterized in temporal and frontal cortex, in hippocampus and in subcortical areas (caudate nucleus and putamen) from controls and patients with Parkinson's disease or progressive supranuclear palsy. The binding affinity (KD) and the maximal specific binding capacity (Bmax) of [3H]MK-801 were unchanged in all the cerebral regions studied in both disease. This indicates the existence of preserved NMDA glutamate receptors, which is required for potential therapeutic efficacy of specific antagonists.</abstract><note type="content">Section title: Research report</note><subject lang="en"><genre>Keywords</genre><topic>N-methyl-d-aspartate receptors</topic><topic>Human brain</topic><topic>[3H]Dizocilpine maleate</topic><topic>Parkinson's disease</topic><topic>Progressive supranuclear palsy</topic><topic>Glutamate antagonist</topic></subject><relatedItem type="host"><titleInfo><title>Brain Research</title></titleInfo><titleInfo type="abbreviated"><title>BRES</title></titleInfo><genre type="journal">journal</genre><originInfo><dateIssued encoding="w3cdtf">19911122</dateIssued></originInfo><identifier type="ISSN">0006-8993</identifier><identifier type="PII">S0006-8993(00)X1481-3</identifier><part><date>19911122</date><detail type="volume"><number>565</number><caption>vol.</caption></detail><detail type="issue"><number>1</number><caption>no.</caption></detail><extent unit="issue pages"><start>1</start><end>179</end></extent><extent unit="pages"><start>154</start><end>157</end></extent></part></relatedItem><identifier type="istex">E84A3C69F12B98A24C9A2D9AFD53ACE76817ACA4</identifier><identifier type="DOI">10.1016/0006-8993(91)91747-O</identifier><identifier type="PII">0006-8993(91)91747-O</identifier><identifier type="ArticleID">9191747O</identifier><recordInfo><recordContentSource>ELSEVIER</recordContentSource></recordInfo></mods></metadata></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000548 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000548 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:E84A3C69F12B98A24C9A2D9AFD53ACE76817ACA4
|texte= [3H]MK-801 binding to NMDA glutamatergic receptors in Parkinson's disease and progressive supranuclear palsy
}}
| This area was generated with Dilib version V0.6.29. |  |